

Implications for Policy and Practice

23 February 2021

16 March 2021

27 April 2021



Webinar 1: Tuesday 23 February 2021 (10am to 1pm)

Introduction Prof Michael Barry

Update on Rapid Review and HTA Assessments Dr Lesley Tilson

European Pharmaceutical Strategy Dr Roisin Adams

Questions and Answers / Break

NCPE Cochrane Review: Importance of Robust Evidence Dr Claire Gorry

HTA Troubleshooting Dr Laura McCullagh

Questions and Answers

Webinar 2: Tuesday 16 March 2021 (10am to 1pm)

Introduction Dr Roisin Adams

Clinical Opinion in HTA Dr Emer Fogarty

Expert Elicitation Niamh Carey

“Cure” Implications for HTA Dr Lea Trela-Larsen

Questions and Answers / Break

COVID ERG Reviews Dr Roisin Adams

Covid-19 Vaccines: A statistical Perspective on the Evidence Dr David McConnell

Questions and Answers

Webinar 3: Tuesday 27 April 2021 (10am to 1pm)

Health Technology Management Prof Michael Barry

Update on Drugs for Rare Diseases Dr Jerome Coffey *Chair of the Rare Diseases
Technology Review Group*

HTA of Drugs for Rare Diseases: Case Study Dr Cara Usher

Questions and Answers / Break

Heterogeneity: Translation into Practice Dr Helen O'Donnell

Transferability of HTAs Between Jurisdictions Dr Claire Gorry

BeNeLuxA: Two Years On Dr Roisin Adams

Questions and Answers